Chroma Medicine Inc. emerged from stealth with $125 million in series A financing and high ambitions to rewrite the rules of genomic medicine by modulating the epigenetic status of target genes in order to switch expression on or off and thereby achieve therapeutic outcomes.
DUBLIN – Genespire Srl, a Milan-based startup led by gene therapy pioneer Luigi Naldini, is the third company to receive funding from Sofinnova Partners’ Italian €108 million (US$117.5 million) gene therapy fund, the Sofinnova Telethon Fund.